Eli Lilly and Company $LLY Shares Sold by Welch & Forbes LLC

Welch & Forbes LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 171,447 shares of the company’s stock after selling 1,257 shares during the period. Eli Lilly and Company accounts for about 2.3% of Welch & Forbes LLC’s investment portfolio, making the stock its 9th largest holding. Welch & Forbes LLC’s holdings in Eli Lilly and Company were worth $198,378,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Coastal Bridge Advisors LLC acquired a new stake in Eli Lilly and Company during the second quarter valued at $2,959,000. Birinyi Associates Inc. lifted its position in shares of Eli Lilly and Company by 32.6% in the third quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock worth $1,689,000 after buying an additional 359 shares during the last quarter. Mosaic Family Wealth Partners LLC boosted its position in Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after purchasing an additional 1,430 shares during the period. Heritage Investors Management Corp grew its holdings in Eli Lilly and Company by 6.5% during the third quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock valued at $13,624,000 after purchasing an additional 718 shares during the last quarter. Finally, Capital Investment Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 51.3% during the 3rd quarter. Capital Investment Advisors LLC now owns 44,851 shares of the company’s stock worth $51,896,000 after buying an additional 15,214 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: In a Phase 3 trial, Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity in adults with obesity or overweight. Lilly reported up to an average 44% reduction in breathing interruptions and said it plans to seek U.S. FDA approval for the indication by year-end 2026. An additional use could expand the pill’s commercial opportunity and help it compete with Novo Nordisk’s obesity treatments. Article: Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial
• Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610 and reiterated a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Article: Jefferies raises Eli Lilly price target
• Positive Sentiment: Lilly is expanding digital access to Zepbound and Foundayo through telehealth partnerships with Hims & Hers and LifeMD, potentially broadening the reach of its branded obesity medicines. Article: Eli Lilly opens digital access to obesity drugs
• Negative Sentiment: The FDA issued new warnings about a potential serious eye risk associated with GLP-1 drugs, including Zepbound. The safety alert may raise concerns for patients and prescribers, although the reports provided no Lilly-specific change to the drug’s safety profile. Article: FDA orders new eye-risk warnings for Ozempic and Zepbound

Eli Lilly and Company Stock Up 4.4%

NYSE:LLY opened at $1,413.22 on Tuesday. The stock’s fifty day moving average price is $1,220.13 and its two-hundred day moving average price is $1,102.83. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.87, a P/E/G ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,453.00. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm’s revenue was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $7.02 earnings per share. On average, analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is currently 22.46%.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research reports. The Goldman Sachs Group reissued a “buy” rating and issued a $1,413.00 price target on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Sanford C. Bernstein restated an “outperform” rating and set a $1,450.00 target price on shares of Eli Lilly and Company in a research report on Monday, October 26th. Leerink Partners upped their price target on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research report on Wednesday, October 21st. Royal Bank Of Canada lifted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a report on Friday, October 30th. Finally, TD Cowen reaffirmed a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,416.64.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.